Research ArticleOpen AccessGoogle Scholar indexed
The Re-Emerging Role of Elective Pelvic Nodal Irradiation in High-Risk Node Negative Prostate Cancer
Department of Clinical Oncology, Imperial College Healthcare NHS Trust, London, UK
- 1 Department of Clinical Oncology, Imperial College Healthcare NHS Trust, London, UK
Journal of Cancer Therapy·Volume 08 (2017)·Pages 1135–1148·Published 12 December 2017·DOI10.4236/jct.2017.813097
Copy link · social · email
Abstract
The benefit of elective nodal irradiation (ENI) in combination with androgen deprivation therapy in high risk localized node negative prostate cancer has yet to be clearly defined. The potential gains in local control have been offset by the increased toxicity associated with pelvic radiotherapy, and recognition that historically the only trials to demonstrate a survival advantage in this group have been with androgen deprivation therapy. This review article considers the impact of pivotal randomized clinical trials conducted over the last thirty years on routine clinical practice, and how modern techniques may help to redefine radiotherapy as a necessary component for this group of patients.
KeywordsProstate CancerPelvic RadiotherapyClinical TrialsAndrogen Deprivation TherapyIMRT
- Zagars, G.K., Pollack, A. and von Eschenbach, A.C. (2001) Addition of Radiation Therapy to Androgen Ablation Improves Outcome for Subclinically Node-Positive Prostate Cancer. Urology, 58, 233-239. https://doi.org/10.1016/S0090-4295(01)01168-2
- Lin, C.C., Gray, P.J., Jemal, A. and Efstathiou, J.A. (2015) Androgen Deprivation with or without Radiation Therapy for Clinically Node-Positive Prostate Cancer. Journal of the National Cancer Institute, 107, djv119. https://doi.org/10.1093/jnci/djv119
- James, N.D., Spears, M.R., Clarke, N.W., Dearnaley, D.P., Mason, M.D., Parker, C.C., et al. (2016) Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. JAMA Oncology, 2, 348-357. https://doi.org/10.1001/jamaoncol.2015.4350
- Langenhuijsen, J.F., van Lin, E.N., Hoffmann, A.L., Spitters-Post, I., Alfred Witjes, J., Kaanders, J.H., et al. (2011) Neoadjuvant Androgen Deprivation for Prostate Volume Reduction: The Optimal Duration in Prostate Cancer Radiotherapy. Urologic Oncology, 29, 52-57. https://doi.org/10.1016/j.urolonc.2009.03.024
- Zietman, A.L., Prince, E.A., Nakfoor, B.M. and Park, J.J. (1997) Androgen Deprivation and Radiation Therapy: Sequencing Studies Using the Shionogi in Vivo Tumor System. International Journal of Radiation Oncology*Biology*Physics, 38, 1067-1070. https://doi.org/10.1016/S0360-3016(97)00309-X
- Dearnaley, D.P., Jovic, G., Syndikus, I., Khoo, V., Cowan, R.A., Graham, J.D., et al. (2014) Escalated-Dose versus Control-Dose Conformal Radiotherapy for Prostate Cancer: Long-Term Results from the MRC RT01 Randomised Controlled Trial. Lancet Oncology, 15, 464-473. https://doi.org/10.1016/S1470-2045(14)70040-3
- Dearnaley, D., Syndikus, I., Sumo, G., Bidmead, M., Bloomfield, D., Clark, C., et al. (2012) Conventional versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy for Prostate Cancer: Preliminary Safety Results from the CHHiP Randomised Controlled Trial. Lancet Oncology, 13, 43-54. https://doi.org/10.1016/S1470-2045(11)70293-5
- Créhange, G., Chen, C.P., Hsu, C.C., Kased, N., Coakley, F.V., Kurhanewicz, J., et al. (2012) Management of Prostate Cancer Patients with Lymph Node Involvement: A Rapidly Evolving Paradigm. Cancer Treatment Reviews, 38, 956-967. https://doi.org/10.1016/j.ctrv.2012.05.005
- Roach, M., Marquez, C., You, H.S., Narayan, P., Coleman, L., Nseyo, U.O., et al. (1994) Predicting the Risk of Lymph Node Involvement Using the Pre-Treatment Prostate Specific Antigen and Gleason Score in Men with Clinically Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics, 28, 33-37. https://doi.org/10.1016/0360-3016(94)90138-4